Skip to main content
. 2022 Nov 8;10(11):e4439. doi: 10.1097/GOX.0000000000004439

Table 3.

Responses Reflect Participant Responses of Strongly Agreeing or Agreeing That They Would Be Less Likely to Receive Breast Implants after They Were Provided with a Given Piece of Information from the FDA Boxed Warning on Breast Implants during the Survey

FDA Boxed Warning Respondent Characteristic OR (95% CI) P
Not considered lifetime devices Hispanic ethnicity 2.35 (1.33–4.39) 0.005
Annual household income ≥$50,000 0.64 (0.42–0.96) 0.033
Risk of BIA-ALCL Hispanic ethnicity 2.04 (1.12–3.94) 0.026
Risk of systemic symptoms Other insurance type* 4.48 (1.39–16.3) 0.016
Annual household income ≥$50,000 0.52 (0.34–0.79) 0.002
Recommendation of initial screening for rupture Hispanic ethnicity 1.78 (1.05–3.09) 0.037
ADH 2.44 (1.47–4.08) <0.001
Private health insurance 0.56 (0.37–0.84) 0.005
Recommendation of continued screening for rupture Hispanic ethnicity 1.74 (1.06–2.92) 0.031
ADH 2.69 (1.62–4.56) <0.001
Interference with mammogram/breast examination Private health insurance 1.70 (1.10–2.66) 0.019
Risk of needing additional operation(s) Hispanic ethnicity 2.39 (1.27–4.85) 0.010
Risk of capsular contracture Hispanic ethnicity 2.11 (1.19–3.96) 0.015

*Respondents had the option to list their insurance type as private coverage, Medicare/Medicaid, or other/not applicable. “Other insurance type” reflects a response of “other/not applicable.”